Related Experiment Video
Updated: Aug 16, 2026

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
Published on: October 14, 2021
Levetiracetam-induced parkinsonism in a Huntington disease patient
Theresa A Zesiewicz1, Juan Sanchez-Ramos, Kelly L Sullivan
1Parkinson's Disease and Movement Disorders Center, NPF Centers of Experience, Department of Neurology, University of South Florida Tampa, Florida 33612, USA. tzesiewi@hsc.usf.edu
Abstract:
The authors present a man with Huntington disease who was treated with levetiracetam (Keppra) in an effort to reduce chorea. Chorea was markedly reduced, but the patient developed parkinsonism and lethargy after 6 weeks of treatment. Symptoms consisted of resting tremor, rigidity, increased dystonia, and gait difficulty. Side effects from levetiracetam resolved completely within 7 days of levetiracetam discontinuation, and chorea returned to baseline.
Related Concept Videos
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Huntington Disease l: Introduction
Parkinson Disease l: Introduction
Parkinson's Disease: Overview
Parkinson Disease ll: Pathophysiology
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
